Inventor · disambiguated record
Yannick Debing
Also filed as: DEBING YANNICK
6 granted patents·8 pending applications·5 citations·filing 2020–2025
70Inventor score
Top patents by PatentIndex Score
14 records- 0192US11820773B2Tricyclic compoundsALIGOS THERAPEUTICS INC·Filed 2021·Granted Nov 21, 2023·2 cites·21 claims
- 0288US11957683B2Bicyclic compoundsALIGOS THERAPEUTICS INC·Filed 2022·Granted Apr 16, 2024·1 cites·46 claims
- 0381US11198699B2Compounds targeting PRMT5ALIGOS THERAPEUTICS INC·Filed 2020·Granted Dec 14, 2021·1 cites·26 claims
- 0479US11591341B2Bicyclic and tricyclic compoundsALIGOS THERAPEUTICS INC·Filed 2020·Granted Feb 28, 2023·1 cites·30 claims
- 0565US2022048922A1Compounds targeting prmt5ALIGOS THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 0665US2024150351A1Bicyclic compoundsALIGOS THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0764US2023382909A1Bicyclic compoundsALIGOS THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0863US12384779B2Bicyclic compoundsALIGOS THERAPEUTICS INC·Filed 2023·Granted Aug 12, 2025·0 cites·18 claims
- 0957US2025382618A1Methods and compositions for inhibiting virusALIGOS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1056US11845752B2Substituted imidazo[1,5-a]pyrazines for the treatment of hepatitis BALIGOS THERAPEUTICS INC·Filed 2021·Granted Dec 19, 2023·0 cites·21 claims
- 1153US2023310481A1Bi- and monocyclic nucleoside analogs for treatment of hepatitis eJANSSEN PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1253US2023201239A1Alkynyl nucleoside analogs for treatment of hepatitis eJANSSEN PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1352US2022112194A1Compounds targeting prmt5ALIGOS THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1452US2023201236A1Spirocyclic nucleoside analogues for the treatment of hepatitis eJANSSEN PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Yannick Debing files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →